Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2411 vs Prolia in Postmenopausal Women With Osteoporosis
NCT03974100Phase 3Completed
- Sponsor
- Sandoz
- Start
- Jul 2019
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of denosumab in postmenopausal osteoporosis, sponsored by Sandoz. Started Jul 2019; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT03974100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974100.